Literature DB >> 7846018

Evaluation of cytology and tumor markers of pure pancreatic juice for the diagnosis of pancreatic cancer at early stages.

S Matsumoto1, H Harada, J Tanaka, K Ochi, T Seno, T Tsurumi, K Kunichika.   

Abstract

To evaluate the value of cytology of pure pancreatic juice (PPJ) and tumor marker determination in PPJ and serum for the diagnosis of early pancreatic cancer (EPC), PPJ was obtained endoscopically from 16 patients with EPC (< 20 mm, confined to pancreas), 16 patients with chronic pancreatitis (CP), and 20 controls. Cutoff levels of CEA, CA19-9, and POA in PPJ were set from ROC curves at 40 ng/ml, 7,500 U/ml, and 1.5 U/ml, respectively. For the differentiation of EPC from CP, the sensitivity of CEA, CA19-9, and POA was 71.4, 42.9, and 50%, respectively; specificity was 93.3, 46.7, and 80%, respectively; and diagnostic accuracy was 82.8, 44.8, and 65.5%, respectively. Determination of serum tumor markers was useless. Sensitivity of cytology was 75%, specificity was 93.8%, and diagnostic accuracy was 84.4%. Combined cytology and CEA determination in PPJ increased the diagnostic accuracy to 93.1%. The combination was useful in supporting and supplementing endoscopic retrograde cholangiopancreatography (ERCP) findings for the correct diagnosis in 11 and 4 patients, respectively, with EPC; in one patient EPC was correctly diagnosed on ERCP findings alone. One of 16 patients with CP showed false-positive results. We conclude that cytology and CEA determination in PPJ with ERCP is a useful combination for the diagnosis of pancreatic cancer even in early stages.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7846018     DOI: 10.1097/00006676-199411000-00012

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  6 in total

Review 1.  Differentiating pancreatic cancer from pseudotumorous chronic pancreatitis.

Authors:  Tony E Yusuf; Manoop S Bhutani
Journal:  Curr Gastroenterol Rep       Date:  2002-04

2.  Pancreatic cyst as a sentinel of in situ carcinoma of the pancreas. Report of two cases.

Authors:  K Yamaguchi; K Nakamura; K Yokohata; S Shimizu; K Chijiiwa; M Tanaka
Journal:  Int J Pancreatol       Date:  1997-12

3.  Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia.

Authors:  Ru Chen; Sheng Pan; Xiaobo Duan; Brad H Nelson; Rob A Sahota; Sarah de Rham; Richard A Kozarek; Martin McIntosh; Teresa A Brentnall
Journal:  Mol Cancer       Date:  2010-06-15       Impact factor: 27.401

Review 4.  The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.

Authors:  Katherine E Poruk; D Z Gay; K Brown; J D Mulvihill; K M Boucher; C L Scaife; M A Firpo; S J Mulvihill
Journal:  Curr Mol Med       Date:  2013-03       Impact factor: 2.222

5.  Adipokines and cytokines in human pancreatic juice: unraveling the local pancreatic inflammatory milieu.

Authors:  Kathryn M Dalbec; C Max Schmidt; Terence E Wade; Sue Wang; Deborah A Swartz-Basile; Henry A Pitt; Nicholas J Zyromski
Journal:  Dig Dis Sci       Date:  2009-09-16       Impact factor: 3.199

Review 6.  Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?

Authors:  Robert S O'Neill; Alina Stoita
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.